First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).
Lauren Christine Harshman
Consultant or Advisory Role - AVEO; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Nils Kroeger
No relevant relationships to disclose
Sun Young Rha
No relevant relationships to disclose
Frede Donskov
Research Funding - Novartis
Lori Wood
Consultant or Advisory Role - Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Srinivas Kiran Tantravahi
No relevant relationships to disclose
Ulka N. Vaishampayan
Consultant or Advisory Role - Dendreon; Janssen Oncology; Novartis; Pfizer
Research Funding - Genentech/Roche; Novartis
Other Remuneration - Dendreon (Speakers Bureau); Genentech/Roche; Janssen Biotech (Speakers Bureau); Medivation (Speakers Bureau); Novartis (Speakers Bureau); Pfizer (Educational Presentation Development); Pfizer (Speakers Bureau)
Brian I. Rini
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Jennifer J. Knox
Consultant or Advisory Role - AVEO
Research Funding - Pfizer
Scott A. North
No relevant relationships to disclose
Mary J. MacKenzie
Honoraria - Novartis; Pfizer
Takeshi Yuasa
No relevant relationships to disclose
Sandy Srinivas
No relevant relationships to disclose
Sumanta Kumar Pal
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Bayer/Onyx; Novartis; Pfizer
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer